CSI Market
Sign In | Register

Kiniksa Pharmaceuticals International Plc (KNSA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access KNSA quarterly Cash Flow →
Examining cash flow movements between Kiniksa Pharmaceuticals International Plc and Dec 31 2021 reveals how Dec 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income59.01
Depreciation & amortization1.55
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-28.53
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.12
Share-based Compensation37.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Issuance Of Stock For Acquisition-
Increase Decrease In Prepaid Expense Right Of Use Assets And Other Assets-
Increase Decrease In Accrued Milestone-
Increase Decrease In Contract With Customer Asset-
Gain On Sale Of Property Plant Equipment-
Increase Decrease In Operating Lease Liabilities3.67
Income taxes13.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable26.13
Increase (Decrease) in Accounts Payable0.14
Increase (Decrease) in Accrued Liabilities37.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-22.48
Other Working Capital15.49
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.37
Discontinued operations0.00
Net Cash flow from Operating Activities137.99
Investing Activities
Capital Expenditures-1.57
Sale of Capital Items0.00
Short-term Investments Proceeds-187.43
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-188.99
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock40.75
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-191.39
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents183.58
Deferred Offering Costs Included In Accrued Expenses And Accounts Payable-
Capital Expenditures Incurred But Not Yet Paid0.08
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities33.02
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow136.42
Total Cash Flow-17.99
4 historic quarters locked

Sign in to unlock the full Kiniksa Pharmaceuticals International Plc cash flow history.

Sign In Create Free Account

About Kiniksa Pharmaceuticals International Plc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-019168

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License